Literature DB >> 15648059

Investigation of genes coding for inflammatory components in Parkinson's disease.

Anna Håkansson1, Lars Westberg, Staffan Nilsson, Silvia Buervenich, Andrea Carmine, Björn Holmberg, Olof Sydow, Lars Olson, Bo Johnels, Elias Eriksson, Hans Nissbrandt.   

Abstract

Several findings obtained recently indicate that inflammation may contribute to the pathogenesis in Parkinson's disease (PD). Genetic variants of genes coding for components involved in immune reactions in the brain might therefore influence the risk of developing PD or the age of disease onset. Five single nucleotide polymorphisms (SNPs) in the genes coding for interferon-gamma (IFN-gamma; T874A in intron 1), interferon-gamma receptor 2 (IFN-gamma R2; Gln64Arg), interleukin-10 (IL-10; G1082A in the promoter region), platelet-activating factor acetylhydrolase (PAF-AH; Val379Ala), and intercellular adhesion molecule 1 (ICAM-1; Lys469Glu) were genotyped, using pyrosequencing, in 265 patients with PD and 308 controls. None of the investigated SNPs was found to be associated with PD; however, the G1082A polymorphism in the IL-10 gene promoter was found to be related to the age of disease onset. Linear regression showed a significantly earlier onset with more A-alleles (P = 0.0095; after Bonferroni correction, P = 0.048), resulting in a 5-year delayed age of onset of the disease for individuals having two G-alleles compared with individuals having two A-alleles. The results indicate that the IL-10 G1082A SNP could possibly be related to the age of onset of PD. Copyright 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15648059     DOI: 10.1002/mds.20378

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  14 in total

Review 1.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

Review 2.  Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Authors:  Heather E Allen Reish; David G Standaert
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

Review 3.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

Review 4.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

5.  The changing microbial environment and chronic inflammatory disorders.

Authors:  Graham Aw Rook
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

Review 6.  The role of anti-inflammatory agents in Parkinson's disease.

Authors:  Edith G McGeer; Patrick L McGeer
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  Review series on helminths, immune modulation and the hygiene hypothesis: the broader implications of the hygiene hypothesis.

Authors:  Graham A W Rook
Journal:  Immunology       Date:  2009-01       Impact factor: 7.397

Review 8.  The role of inflammation in sporadic and familial Parkinson's disease.

Authors:  Michela Deleidi; Thomas Gasser
Journal:  Cell Mol Life Sci       Date:  2013-05-12       Impact factor: 9.261

9.  Ifngr1 and Stat1 mediated canonical Ifn-γ signaling drives nigrostriatal degeneration.

Authors:  Michael R Strickland; Emily J Koller; Doris Z Deng; Carolina Ceballos-Diaz; Todd E Golde; Paramita Chakrabarty
Journal:  Neurobiol Dis       Date:  2017-11-28       Impact factor: 5.996

10.  Does neuroinflammation fan the flame in neurodegenerative diseases?

Authors:  Tamy C Frank-Cannon; Laura T Alto; Fiona E McAlpine; Malú G Tansey
Journal:  Mol Neurodegener       Date:  2009-11-16       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.